CD19 and neoplasm: We next investigated the therapeutic efficacy of ↑[H+]-expanded CD19 chimeric-antigen-receptor-modified (CAR) T cells with an in vivo tumor model in which CD19-K562 tumor cells were subcutaneously injected into the flanks of NCG mice (Fig. 5h).